Develops Bioactive Molecules That Regulate Biological Processes Professor Shin Injae's Research Team
Prof. Shin has been devoted to the functional studies of proteins and carbohydrates with synthetic organic compounds since 1998 after joining Yonsei University. His research has focused on the following research fields: 1) synthesis of various organic compounds including small molecules, carbohydrates and peptides, 2) the discovery of novel bioactive molecules that regulate proteins in cells, 3) development of microarrays that can be applied to rapid analysis of biomolecule-associated recognition events, and 4) exploitation of disease targeting drug delivery systems.
As a result of this effort, his research group has reported the first high-density carbohydrate microarrays (Angew Chem Int Ed and Nat Protoc). This microarray has received considerable attention as one of core technologies in functional glycomics. In addition, his group has identified the first small molecule which induces neurogenesis of human muscle cells (J Am Chem Soc and Nat Protoc). As part of the research on neurogenesis inducing small molecules, prof. Shin has opened the new research area termed ‘small molecule-based cellular alchemy’. Furthermore, his research group has discovered a novel inhibitor of Hsp70 and Hsc70 which can be used in cancer treatment (Angew Chem Int Ed, 2008). In collaboration with prof. Wan Nam-kung (Yonsei pharmacy), prof. Jonathan L. Sessler (the University of Texas at Austin) and prof. Philip A. Gale (University of Southampton), prof. Shin’s team recently developed synthetic ion transporters that induce apoptosis, the natural process of programmed cell death. This work has published in Nat Chem under the title “Synthetic ion transporters can induce apoptosis by facilitating chloride anion transport into cells.” As a continuing work, the same research team has exploited more active squaramide-based ion transporters which promote cell death by inducing apoptosis and disrupting autophagy. His final research goal is to develop small molecule-based drug candidates to treat various diseases.